Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis
High doses of cysteamine <i>in vitro</i> reduce the percentages of PPD- and SEB-induced Th1 and Tc1 cells and induce late apoptosis and necrosis. Differently, cysteamine at lower doses retains the immunomodulatory effect without affecting cell viability. These findings suggest cysteamine as a potential adjunct to antimicrobial regimens as in the TB or COVID-19 field, for its ability to reduce the inflammatory status.
Authors
- Chiara Farroni (ORCID: https://orcid.org/0000-0002-2425-9936)
- Anna Maria Gerarda Altera
- Emanuele Nicastri (ORCID: https://orcid.org/0000-0002-5606-8712)
- Mauro Piacentini (ORCID: https://orcid.org/0000-0003-2919-1296)
- Gina Gualano (ORCID: https://orcid.org/0000-0001-6149-0005)
- Gilda Cuzzi (ORCID: https://orcid.org/0000-0002-4305-2199)
- Delia Goletti (ORCID: https://orcid.org/0000-0001-8360-4376)
- Tonino Alonzi (ORCID: https://orcid.org/0000-0002-7706-5828)
- Saeid Najafi Fard (ORCID: https://orcid.org/0000-0001-9957-8934)
- Valentina Vanini (ORCID: https://orcid.org/0000-0001-8476-964X)
- Linda Petrone (ORCID: https://orcid.org/0000-0002-2593-3478)
- Fabrizio Palmieri (ORCID: https://orcid.org/0000-0001-8184-6291)
- Andrea Salmi (ORCID: https://orcid.org/0000-0002-6755-3457)
Institutions
- University of Rome Tor Vergata (IT)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fimmu.2024.1411827
- Citations
- 3
- Primary Topic
- Biomedical Research and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- European Commission
- Ministero della Salute